Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Fox Chase Cancer Center Clear all
Completed Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT00397982
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus, Therapeutic Conventional Surgery
Biological · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 1, 2026, 10:06 PM EDT
Recruiting Early Phase 1 Interventional

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

NCT07167446
View directory record Official record
Conditions
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
Interventions
Cannabidiol (CBD), oxaliplatin-based chemotherapy
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer

NCT00315185
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Drexel Hill, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Sep 1, 2026, 10:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

NCT03113071
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Digoxin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

NCT03302247
View directory record Official record
Conditions
Non Small Cell Lung Cancer Stage IIIB
Interventions
Nivolumab, Nivolumab+Gemcitabine
Biological · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

NCT00002509
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, mesna, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2010 · Synced Sep 1, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional

Testing Gene PilotLX With Latinx Cancer Patients

NCT06476938
View directory record Official record
Conditions
Cancer
Interventions
Gene PilotLX
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Camden, New Jersey • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Completed No phase listed Observational

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT01982591
View directory record Official record
Conditions
Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Paoli, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 1, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

NCT01539174
View directory record Official record
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 1, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

NCT02449213
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
35 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Recruiting Phase 3 Interventional

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

NCT05454280
View directory record Official record
Conditions
Surgery, Cancer
Interventions
Intensified post-discharge surveillance, Standard post-discharge surveillance
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Withdrawn Phase 1 Interventional

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279
View directory record Official record
Conditions
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
Drug · Procedure · Other + 2 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Coping Together After Breast Cancer

NCT03930797
View directory record Official record
Conditions
Breast Cancer
Interventions
Intimacy Enhancement, Living Healthy Together
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

NCT01470365
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
quality-of-life assessment, intensity-modulated radiation therapy, 3-dimensional conformal radiation therapy
Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

NCT01288534
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 1, 2026, 10:06 PM EDT
Active, not recruiting Not applicable Interventional

Penn Medicine Biobank Return of Results Program

NCT06089954
View directory record Official record
Conditions
Genetic Disease, Cancer, Cardiovascular Diseases
Interventions
private web-portal eHealth disclosure of genetic results, eHealth education intervention (web or chatbot)
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

A Web-Based Multimedia Intervention for Head and Neck Cancer Patients

NCT02442336
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
My Journey AHead
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

NCT00021320
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 1, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT02755272
View directory record Official record
Conditions
Carcinoma Breast Stage IV
Interventions
Pembrolizumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Indianapolis, Indiana • St Louis, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT03172754
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Axitinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Albany, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

NCT02132845
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis
Other · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Not listed Phase 4 Interventional

Buprenorphine for Cancer Pain

NCT05910190
View directory record Official record
Conditions
Cancer-Related Pain
Interventions
Use of buprenorphine with FAO > 30 OME, CPM Rx application use
Drug · Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

NCT00350025
View directory record Official record
Conditions
Urologic Neoplasm
Interventions
Cetuximab, Paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 1, 2026, 10:06 PM EDT
Withdrawn Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00054392
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
57
States / cities
Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 1, 2026, 10:06 PM EDT